CA2067744A1 - Recepteur (cr1) c3b/c4b humain - Google Patents
Recepteur (cr1) c3b/c4b humainInfo
- Publication number
- CA2067744A1 CA2067744A1 CA2067744A CA2067744A CA2067744A1 CA 2067744 A1 CA2067744 A1 CA 2067744A1 CA 2067744 A CA2067744 A CA 2067744A CA 2067744 A CA2067744 A CA 2067744A CA 2067744 A1 CA2067744 A1 CA 2067744A1
- Authority
- CA
- Canada
- Prior art keywords
- fragments
- expression
- protein
- proteins
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne le gène de récepteur (CR1) de C3b/C4b, sa protéine codée, ainsi que des séquences d'acides nucléiques de CR1 et des fragments de celles-ci comprenant 70 nucléotides, ainsi que leurs peptides ou protéines codées comprenant 24 acides aminés. L'invention concerne également l'expression de la protéine CR1 ainsi que de fragments de celle-ci. Les gènes et les protéines de l'invention présentent des utilisations dans le diagnostic et la thérapie de troubles appliquant une activité du complément, et divers modes de réalisation de l'invention comprennent le clonage, une séquence de nucléotides ainsi qu'une séquence d'acides aminés déduite d'un ADN complémentaire de CR1 de longueur intégrale ainsi que ses fragments. L'expression de la protéine CR1 et de fragments de celle-ci est également décrite, ainsi que l'expression d'une molécule de CR1 secrétée à laquelle il manque une région de transmembrane, laquelle est utile pour réduire la détérioration provoquée par l'inflammation, et pour réduire la taille de l'infarctus du myocarde et pour prévenir les blessures de reperfusion.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41274589A | 1989-09-26 | 1989-09-26 | |
US412,745 | 1989-09-26 | ||
US588,128 | 1990-09-24 | ||
US07/588,128 US5256642A (en) | 1988-04-01 | 1990-09-24 | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
PCT/US1990/005454 WO1991005047A1 (fr) | 1989-09-26 | 1990-09-25 | RECEPTEUR (CR1) DE C3b/C4b HUMAINS |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2067744A1 true CA2067744A1 (fr) | 1991-03-27 |
CA2067744C CA2067744C (fr) | 2001-02-06 |
Family
ID=27021901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002067744A Expired - Fee Related CA2067744C (fr) | 1989-09-26 | 1990-09-25 | Recepteur (cr1) c3b/c4b humain |
Country Status (15)
Country | Link |
---|---|
US (3) | US5256642A (fr) |
EP (1) | EP0502892B1 (fr) |
JP (1) | JP3097753B2 (fr) |
CN (1) | CN1060112A (fr) |
AT (1) | ATE256181T1 (fr) |
AU (1) | AU656312B2 (fr) |
CA (1) | CA2067744C (fr) |
DE (1) | DE69034122D1 (fr) |
FI (1) | FI921291A0 (fr) |
GR (1) | GR900100716A (fr) |
IE (1) | IE903447A1 (fr) |
IL (1) | IL95806A (fr) |
NZ (1) | NZ235445A (fr) |
PT (1) | PT95437B (fr) |
WO (1) | WO1991005047A1 (fr) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
AU9149791A (en) * | 1990-12-06 | 1992-07-08 | T Cell Sciences, Inc. | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
EP0512733A2 (fr) * | 1991-05-03 | 1992-11-11 | Washington University | Régulateur modifié du système complémentaire |
CA2135390A1 (fr) * | 1992-05-11 | 1993-11-25 | Matthew Moyle | Nouveaux inhibiteurs du neutrophile |
US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
TW262386B (fr) * | 1992-09-30 | 1995-11-11 | Senju Pharma Co | |
GB9301289D0 (en) * | 1993-01-22 | 1993-03-17 | Smithkline Beecham Plc | Novel composition |
DE69431290D1 (de) | 1993-02-12 | 2002-10-10 | Avant Immunotherapeutics Inc | PULMONÄRE VERABREICHUNG DES LÖSLICHEN KOMPLEMENT-RECEPTORS TYP 1 sCR1 |
US5520912A (en) * | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
US5840858A (en) * | 1993-07-09 | 1998-11-24 | T Cell Sciences, Inc. | Protein purification using immobilized metal affinity chromatography for complement receptor proteins |
US5861272A (en) * | 1995-06-02 | 1999-01-19 | Human Genome Sciences, Inc. | C5A receptor |
FI951778A (fi) * | 1995-04-12 | 1996-10-13 | Aboatech Ab Oy | Menetelmä allergian toteamiseksi |
GB9604518D0 (en) * | 1996-03-02 | 1996-05-01 | Smithkline Beecham Plc | Novel compounds |
JP2000505068A (ja) | 1996-03-13 | 2000-04-25 | トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | 補体活性化を阻害する新規ペプチド類 |
BR9708387A (pt) | 1996-03-28 | 2000-01-04 | Genitrix Llc | Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada. |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
GB9614871D0 (en) | 1996-07-15 | 1996-09-04 | Smithkline Beecham Plc | Compounds |
US6319890B1 (en) * | 1996-12-30 | 2001-11-20 | Manfred P. Dierich | Inhibition of binding of complement Factor H |
JP2001515589A (ja) * | 1997-03-06 | 2001-09-18 | バイオン ダイアグノスティック サイエンシーズ,インコーポレイテッド | 補体レギュレーターまたはレセプタータンパク質を使用するスクリーニングおよび処置 |
US6221621B1 (en) | 1997-03-06 | 2001-04-24 | Bard Diagnostic Sciences, Inc. | Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated |
WO1998040743A1 (fr) * | 1997-03-10 | 1998-09-17 | Beth Israel Deaconess Medical Center | Complexes immuns, procede de detection et traitement de ces complexes |
US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
US6503947B1 (en) | 1998-01-27 | 2003-01-07 | Brigham And Women's Hospital | Method of treating cytotoxic damage |
US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
US6956107B2 (en) * | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
KR100425965B1 (ko) * | 1998-02-20 | 2004-04-06 | 타녹스 인코퍼레이티드 | 보체 활성화의 억제물질 |
US6297024B1 (en) | 1998-10-15 | 2001-10-02 | Cell Activation, Inc. | Methods for assessing complement activation |
US6235494B1 (en) | 1999-02-08 | 2001-05-22 | The Scripps Research Institute | Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates |
US20020102581A1 (en) * | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
GB9905503D0 (en) | 1999-03-10 | 1999-05-05 | Adprotech Plc | Novel compound formulations and methods of delivery |
US7011952B2 (en) | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
US20030118983A1 (en) * | 2000-03-09 | 2003-06-26 | Cassidy Richard A. | Rapid screening procedure for inflammation mediators |
DE60136272D1 (de) * | 2000-04-29 | 2008-12-04 | Univ Iowa Res Found | Diagnostika und therapeutika für makula degeneration erkrankungen |
GB0016811D0 (en) * | 2000-07-07 | 2000-08-30 | Adprotech Ltd | Lipid rafts |
US20030050692A1 (en) * | 2000-12-22 | 2003-03-13 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
US20020082679A1 (en) * | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US6820011B2 (en) * | 2001-04-11 | 2004-11-16 | The Regents Of The University Of Colorado | Three-dimensional structure of complement receptor type 2 and uses thereof |
JP2005538953A (ja) * | 2002-05-28 | 2005-12-22 | 3−ディメンショナル ファーマシューティカルズ, インコーポレイテッド | 新規チオフェンアミジン、それらの組成物、および補体媒介疾患および病気を治療する方法 |
AU2003275075A1 (en) | 2002-09-20 | 2004-04-08 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved activity |
JP4915980B2 (ja) * | 2002-11-15 | 2012-04-11 | エムユーエスシー ファウンデーション フォー リサーチ デベロップメント | 補体レセプター2標的化補体調節因子 |
WO2005069726A2 (fr) * | 2004-01-21 | 2005-08-04 | Case Western Reserve University | Polypeptides hybrides et chimeriques regulant l'activation du complement |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
EP1814576A2 (fr) * | 2004-07-20 | 2007-08-08 | Critical Therapeutics, Inc. | Therapie contre l'inflammation combinant le hmgb et les inhibiteurs du complement |
EP1738763A1 (fr) | 2005-06-30 | 2007-01-03 | AVANT Immunotherapeutics, Inc. | Utilisation de proteines d'inhibition du système complémentaire pour le traitement d'und lesion de la moelle épinière |
CN1314811C (zh) * | 2005-07-25 | 2007-05-09 | 中国人民解放军第四军医大学 | 重组嵌合分子Cb1-Grb7(SH2)-RING真核表达质粒及抗肿瘤基因药物用途 |
NZ567483A (en) * | 2005-11-04 | 2012-04-27 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
EP2377878B1 (fr) * | 2005-11-28 | 2018-03-28 | The Trustees Of The University Of Pennsylvania | Analogues puissants de la compstatine |
US20070196367A1 (en) * | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
MX2008011323A (es) | 2006-03-08 | 2008-11-18 | Archemix Corp | Aptameros que se unen al complemento y agentes anti-c5 utiles en el tratamiento de trastornos oculares. |
DE102006019296A1 (de) * | 2006-04-26 | 2007-10-31 | Robert Bosch Gmbh | Zündspule, insbesondere für eine Brennkraftmaschine eines Kraftfahrzeugs |
PT2044111E (pt) | 2006-06-21 | 2014-11-12 | Univ Colorado Regents | Abordagem seletiva do fator h do complemento para o tratamento de doenças |
PT3028716T (pt) | 2006-10-10 | 2020-11-23 | Regenesance B V | Inibição do complemento para regeneração nervosa melhorada |
EP2907827B1 (fr) * | 2006-11-02 | 2018-09-19 | Genentech, Inc. | Anticorps humanisés anti-facteur D et leurs utilisations |
WO2008079371A1 (fr) * | 2006-12-22 | 2008-07-03 | Encysive Pharmaceuticals, Inc. | Modulateurs du récepteur du c3a et leurs procédés d'utilisation |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
CN102245765B (zh) | 2008-10-21 | 2015-01-07 | 通用医院公司 | 细胞移植 |
GB0904427D0 (en) * | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
AU2010266127B2 (en) | 2009-07-02 | 2015-11-05 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
KR20120130748A (ko) | 2009-11-05 | 2012-12-03 | 알렉시온 캠브리지 코포레이션 | 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료 |
EP2569332B1 (fr) | 2010-05-14 | 2019-01-09 | The Regents of the University of Colorado, A Body Corporate | Groupes de ciblage des récepteurs 2 du complément (cr2) améliorés |
CA2803588A1 (fr) | 2010-06-22 | 2011-12-29 | The Regents Of The University Of Colorado, A Body Corporate | Anticorps contre le fragment c3d du composant 3 du complement |
CN103153376B (zh) | 2010-08-06 | 2018-04-20 | 通用医院公司以麻省总医院名义经营 | 用于细胞处理相关应用的系统和设备 |
CN102702339B (zh) * | 2011-05-24 | 2013-10-30 | 华南师范大学 | 斜带石斑鱼补体c3基因、载体、重组菌株和蛋白及其应用 |
WO2013036778A2 (fr) | 2011-09-07 | 2013-03-14 | The Trustees Of The University Of Pennsylvania | Analogues de compstatine ayant des propriétés pharmacocinétiques améliorées |
WO2013082458A1 (fr) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Solution de protection de reperfusion et ses utilisations |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
SG11201601044XA (en) | 2013-08-12 | 2016-03-30 | Genentech Inc | Compositions and method for treating complement-associated conditions |
MA39934A (fr) | 2014-05-01 | 2017-03-08 | Hoffmann La Roche | Variants d'anticorps anti-facteur d et leurs utilisations |
US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
CN108472382A (zh) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体变体缀合物及其用途 |
CA3096078A1 (fr) | 2018-04-06 | 2019-10-10 | The Trustees Of The University Of Pennsylvania | Analogues de la compstatine possedant une solubilite augmentee et des proprietes pharmacocinetiques ameliorees |
KR20210013091A (ko) * | 2018-05-16 | 2021-02-03 | 시에스엘 리미티드 | 가용성 보체 수용체 1형 변이체 및 이의 용도 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212071A (en) * | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
NZ191320A (en) * | 1978-09-07 | 1982-09-14 | Beecham Group Ltd | In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions |
EP0028489B1 (fr) * | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Dérivés d'enzymes et leur préparation |
US4642284A (en) * | 1983-06-13 | 1987-02-10 | Scripps Clinic And Research Foundation | Method and system for detection of complement pathway activation |
US4713332A (en) * | 1984-01-13 | 1987-12-15 | The Ontario Cancer Institute | T cell specific CDNA clone |
US4672044A (en) * | 1984-08-24 | 1987-06-09 | Scripps Clinic & Research Foundation | Murine monoclonal antibody combining site to human C3b receptor (CR1) |
US4761371A (en) * | 1985-02-12 | 1988-08-02 | Genentech, Inc. | Insulin receptor |
US4886743A (en) * | 1985-04-24 | 1989-12-12 | California Institute Of Technology | Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof |
JPH0742235B2 (ja) * | 1985-11-08 | 1995-05-10 | 三共株式会社 | 自己免疫性疾病の予防・治療剤 |
IL89790A (en) * | 1988-04-01 | 2002-05-23 | Johns Hopking University | Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification |
AT402153B (de) * | 1989-06-26 | 1997-02-25 | Immuno Ag | Protein-s-hältige pharmazeutische präparation |
IL94522A (en) * | 1990-05-28 | 1994-02-27 | Joseph Eldor | Device for combined spinal and epidural anesthesia |
-
1990
- 1990-09-24 US US07/588,128 patent/US5256642A/en not_active Expired - Lifetime
- 1990-09-25 EP EP90917286A patent/EP0502892B1/fr not_active Expired - Lifetime
- 1990-09-25 CA CA002067744A patent/CA2067744C/fr not_active Expired - Fee Related
- 1990-09-25 NZ NZ235445A patent/NZ235445A/en unknown
- 1990-09-25 WO PCT/US1990/005454 patent/WO1991005047A1/fr active IP Right Grant
- 1990-09-25 IE IE344790A patent/IE903447A1/en not_active Application Discontinuation
- 1990-09-25 AU AU67550/90A patent/AU656312B2/en not_active Ceased
- 1990-09-25 DE DE69034122T patent/DE69034122D1/de not_active Expired - Lifetime
- 1990-09-25 AT AT90917286T patent/ATE256181T1/de not_active IP Right Cessation
- 1990-09-25 JP JP03500358A patent/JP3097753B2/ja not_active Expired - Fee Related
- 1990-09-26 IL IL95806A patent/IL95806A/en not_active IP Right Cessation
- 1990-09-26 GR GR900100716A patent/GR900100716A/el not_active IP Right Cessation
- 1990-09-26 PT PT95437A patent/PT95437B/pt active IP Right Grant
- 1990-11-30 CN CN90109580A patent/CN1060112A/zh active Pending
-
1992
- 1992-03-25 FI FI921291A patent/FI921291A0/fi unknown
-
1993
- 1993-10-19 US US08/138,825 patent/US5472939A/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/472,038 patent/US5856297A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
IE903447A1 (en) | 1991-04-10 |
EP0502892A4 (en) | 1992-11-19 |
JPH05504053A (ja) | 1993-07-01 |
PT95437B (pt) | 1998-12-31 |
IL95806A (en) | 1998-04-05 |
AU6755090A (en) | 1991-04-28 |
PT95437A (pt) | 1991-08-14 |
IL95806A0 (en) | 1991-06-30 |
WO1991005047A1 (fr) | 1991-04-18 |
ATE256181T1 (de) | 2003-12-15 |
US5256642A (en) | 1993-10-26 |
EP0502892B1 (fr) | 2003-12-10 |
US5856297A (en) | 1999-01-05 |
FI921291A (fi) | 1992-03-25 |
AU656312B2 (en) | 1995-02-02 |
EP0502892A1 (fr) | 1992-09-16 |
GR900100716A (el) | 1992-01-20 |
CA2067744C (fr) | 2001-02-06 |
NZ235445A (en) | 1993-02-25 |
US5472939A (en) | 1995-12-05 |
CN1060112A (zh) | 1992-04-08 |
DE69034122D1 (de) | 2004-01-22 |
FI921291A0 (fi) | 1992-03-25 |
JP3097753B2 (ja) | 2000-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2067744A1 (fr) | Recepteur (cr1) c3b/c4b humain | |
IL89790A0 (en) | Human c3b/c4b receptor(cr1) | |
Jacobs et al. | Isolation of a cDNA clone encoding a high molecular weight precursor to a 6-kDa pulmonary surfactant-associated protein. | |
DE69733204T2 (de) | Neuartige vegf-ähnliche faktoren | |
US20020034787A1 (en) | Fibroblast growth factor-10 | |
US5401651A (en) | DNA encoding ENA-78, a neutrophil activating factor | |
CA2529179A1 (fr) | Vecteur viral aav recombine pour traitement de la maladie d'alzheimer | |
JP2007289186A (ja) | Dp75をコードするdnaおよびその使用のための工程 | |
KR970705405A (ko) | 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides) | |
NZ503235A (en) | Amino-terminally truncated RANTES as chemokine antagonists | |
EP1217067A2 (fr) | Facteur de croissance 2 de tissu conjonctif | |
DE3588224T2 (de) | Gereinigtes Interleukin-1 und für Interleukin-1 kodierende DNS und deren Herstellung, solche DNS enthaltende Vektoren und deren Herstellung und Verwendung zum Transformieren von Wirten, die die Expression von Interleukin-1 zulassen | |
PT98695A (pt) | Gene codificador do factor neurotrofico de ligacao a heparina | |
CA2342770A1 (fr) | Gene ly6h | |
US20030175260A1 (en) | Novel DNA and a process for its use | |
AU617999B2 (en) | A genetic engineering process for the preparation of angiogenins | |
EP0913470A3 (fr) | Récepteur C3b/C4b humain (CR1) | |
KR930701475A (ko) | 사람의 거핵구-집락 촉진 인자(hMeg-CSF) 및 그것의 생산방법 | |
CA2250433A1 (fr) | Dnase ii humaine | |
EP0502876B1 (fr) | Nouvelles proteines dissolvant les caillots sanguins, et leur preparation a partir de la sangsue hirudo medicinalis | |
EP0308424A1 (fr) | Nouvelle proteine designee neuroleukine | |
KR20010030984A (ko) | 폴리펩티드, 그 폴리펩티드를 암호화하는 cDNA 및이들의 용도 | |
WO2000064464A8 (fr) | Acides nucleiques et proteines d'une alpha1→2fucosyltransferase specifique du ganglioside gm1 murin, et leurs utilisations | |
JPH06500070A (ja) | 新規タンパク質及びその製造 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDC | Discontinued application reinstated | ||
MKLA | Lapsed | ||
MKLA | Lapsed |
Effective date: 20080925 |